Single Center Experience Study with Pembrolizumab in Patients with BRAF Mutant Negative Metastatic Melanoma
Abstract The aim of the paper was to determine the efficacy, toxicity and progression free survival with anti-PD-1 immunotherapy pembrolizumab in BRAF wild type metastatic melanoma patients with good performance status (ECOG PS 0-1). From February 2017 to April 2018, 17 patients with BRAF mutant wild type metastatic melanoma were enrolled in th...
By IVICA PEJČIĆ, IVAN PETKOVIĆ, ANA CVETANOVIĆ, IRENA CONIĆ